Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 4 Number and percentagec of manufacturers of generics and branded generics by licensure type over timeb

From: The Brazilian private pharmaceutical market after the first ten years of the generics law

Selected medicinesa 2002 2006 2010
Branded generics Generics Generics + Branded generics Branded generics Generics Generics + Branded generics Branded generics Generics Generics + Branded generics
N % N % N % N % N % N % N % N % N %
Antibiotics
 Penicillins 36 78.3 3 6.5 7 15.2 32 68.1 6 12.8 9 19.1 15 41.7 7 19.4 14 38.9
 Fluoroquinolones 29 85.3 2 5.9 3 8.8 36 69.2 9 17.3 7 13.5 22 47.8 12 26.1 12 26.1
 Cephalosporins 19 73.1 2 7.7 5 19.2 20 57.1 8 22.9 7 20 11 39.3 7 25 10 35.7
 Macrolides 29 82.9 1 2.9 5 14.3 31 72.1 2 4.7 10 23.3 23 57.5 7 17.5 10 25
Antidiabetics
 Glibenclamide 11 91.7 1 8.3 0 0 15 71.4 5 23.8 1 4.8 12 57.1 8 38.1 1 4.8
 Glimepiride 2 100 0 0 0 0 9 69.2 3 23.1 1 7.7 6 35.3 9 52.9 2 11.8
 Metformin 4 66.7 1 16.7 1 16.7 13 56.5 9 39.1 1 4.3 13 41.9 15 48.4 3 9.7
Antihypertensives
 Methyldopa 12 92.3 1 7.7 0 0 13 76.5 2 11.8 2 11.8 7 63.6 2 18.2 2 18.2
 Diuretics 20 90.9 1 4.5 1 4.5 27 77.1 5 14.3 3 8.6 22 68.8 6 18.8 4 12.5
 Betablockers 13 76.5 2 11.8 2 11.8 17 60.7 6 21.4 5 17.9 15 48.4 9 29 7 22.6
 Calcium antagonists 18 81.8 2 9.1 2 9.1 24 63.2 8 21.1 6 15.8 16 48.5 11 33.3 6 18.2
 ACE inhibitorsd 26 78.8 3 9.1 4 12.1 37 71.2 8 15.4 7 13.5 33 62.3 12 22.6 8 15.1
  1. aIncluded are only antidiabetic, antihypertensive and antidiabetic molecules which had generics in the market during the study period
  2. bTime points are the first quarter of the respective year
  3. cDenominators are the total number of manufacturers of branded generics and generics in each period
  4. dACE = Angiotensin-converting enzyme